MetaVia Inc.
A clinical-stage biotech developing novel drugs for cardiometabolic diseases like obesity and MASH.
MTVA | NDAQ
Overview
Corporate Details
- ISIN(s):
- US64132R1077
- LEI:
- Country:
- United States of America
- Address:
- 545 CONCORD AVENUE, 2138 CAMBRIDGE
- Website:
- https://metaviatx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases. The company's pipeline includes DA-1726, a dual GLP-1/glucagon receptor agonist in development for the treatment of obesity, and Vanoglipel, a G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of MASH (Metabolic dysfunction-associated steatohepatitis). Formerly known as NeuroBo Pharmaceuticals, the company is dedicated to advancing therapies for complex metabolic disorders.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all MetaVia Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for MetaVia Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for MetaVia Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
